Cenegermin (Oxervate): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
[No authors listed]
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.
PMID:38723125
PERSISTENT CORNEAL EPITHELIAL DEFECT AFTER PARS PLANA VITRECTOMY.